- •Gemcitabine/carboplatin and gemcitabine/oxaliplatin had similar efficacy.
- •The toxicity profile differed between the two regimens.
- •Haematological toxicities and fatigue were more common in the gemcitabine/carboplatin arm.
- •Peripheral sensory neuropathy was more common in the gemcitabine/oxaliplatin arm.
Gemcitabine–oxaliplatin (GEMOX) demonstrated mild toxicity and promising effectiveness in patients with advanced urothelial cell cancer (UCC). We investigated the activity and safety of first-line GEMOX compared with gemcitabine–carboplatin (GCb) in cisplatin-ineligible patients with advanced UCC.
Treatment-naive, cisplatin-ineligible patients with advanced UCC were randomly assigned to GEMOX (gemcitabine 1000 mg/m2, oxaliplatin 100 mg/m2 on day 1 [D1] every 2 weeks) or GCb (1000 mg/m2 of gemcitabine on D1 and D8 and carboplatin area under the curve of 4.5 mg/mL/min on D1 every 3 weeks). We evaluated the objective response rate (ORR), progression-free survival (PFS) and overall survival (OS).
Between January 2011 and March 2017, 80 patients were enrolled; 39 and 40 patients were allocated to GCb and GEMOX arms, respectively. The ORR was 48.7% in the GCb arm and 55.0% in the GEMOX arm. The median follow-up duration was 37.8 months; the median PFS and OS in the GCb and GEMOX arms were 5.5 months (95% confidence interval [CI], 4.8–6.2) vs. 4.4 months (95% CI, 2.7–6.1) and 9.1 months (95% CI, 5.2–13.0) vs. 11.0 months (95% CI, 6.9–15.0), respectively. Leucopenia, neutropenia and fatigue of grade III were significantly more common in the GCb arm (26% vs. 3%, P = 0.003; 33% vs. 10%, P = 0.014; 15% vs. 3%, P = 0.012), whereas any-grade neuropathy was more common in the GEMOX arm (8% vs. 60%).
GEMOX showed similar efficacy with GCb and a favourable haematologic toxicity profile. GEMOX may be an additional chemotherapy option for patients with UCC ineligible for cisplatin-containing chemotherapy (NCT01487915).
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to European Journal of Cancer
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Evolving treatment of advanced urothelial cancer.J Oncol Pract. 2017; 13: 309-315https://doi.org/10.1200/JOP.2017.022137
- Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.J Clin Oncol. 2000; 18: 3068-3077
- Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: european Organization for Research and Treatment of Cancer Protocol no. 30924.J Clin Oncol. 2001; 19: 2638-2646https://doi.org/10.1200/JCO.2001.19.10.2638
- Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.J Clin Oncol. 2011; 29: 2432-2438https://doi.org/10.1200/JCO.2011.34.8433
- Randomized phase II/III trial comparing gemcitabine/carboplatin (GC) and methotrexate/carboplatin/vinblastine (M-CAVI) in patients (pts) with advanced urothelial cancer (UC) unfit for cisplatin-based chemotherapy (CHT): phase III results of EORTC study 30986.J Clin Oncol. 2010; 28: LBA4519
- Platinum antitumor complexes: 50 Years since barnett rosenberg's discovery.J Clin Oncol. 2015; 33: 4219-4226https://doi.org/10.1200/JCO.2015.60.7481
- Supraadditive effect of 2',2'-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines.Cancer Chemother Pharmacol. 1999; 44: 117-123https://doi.org/10.1007/s002800050955
- Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the eastern cooperative Oncology Group.J Clin Oncol. 2009; 27: 3778-3785https://doi.org/10.1200/jco.2008.20.9007
- Combination of gemcitabine and oxaliplatin in urothelial cancer patients with severe renal or cardiac comorbidities.Anti Cancer Drugs. 2005; 16: 1017-1021https://doi.org/10.1097/01.cad.0000176503.48433.74
- A phase II monocentric study of oxaliplatin in combination with gemcitabine (GEMOX) in patients with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract.Ann Oncol. 2006; 17: 990-994https://doi.org/10.1093/annonc/mdl057
- Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer.Ann Oncol. 2007; 18: 1359-1362https://doi.org/10.1093/annonc/mdm160
- Gemcitabine or gemcitabine plus oxaliplatin in the first-line treatment of patients with advanced transitional cell carcinoma of the urothelium unfit for cisplatin-based chemotherapy: a randomized phase 2 study of the French Genitourinary Tumor Group (GETUG V01).Eur Urol. 2011; 60: 1251-1257https://doi.org/10.1016/j.eururo.2011.08.072
- A phase II study of gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the bladder.Cancer Chemother Pharmacol. 2013; 72: 263-267https://doi.org/10.1007/s00280-013-2178-x
- Pembrolizumab as second-line therapy for advanced urothelial carcinoma.N Engl J Med. 2017; 376: 1015-1026https://doi.org/10.1056/NEJMoa1613683
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.Lancet. 2017; 389: 67-76https://doi.org/10.1016/S0140-6736(16)32455-2
- Updated efficacy and safety of KEYNOTE-052: a single-arm phase 2 study investigating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC).J Clin Oncol. 2018; 36: 4524https://doi.org/10.1200/JCO.2018.36.15_suppl.4524
Published online: October 24, 2019
Accepted: August 18, 2019
Received in revised form: June 22, 2019
Received: April 14, 2019
© 2019 Elsevier Ltd. All rights reserved.
ScienceDirectAccess this article on ScienceDirect
- Is it time to redefine cisplatin ineligibility in metastatic urothelial cancer?European Journal of CancerVol. 127
- PreviewCisplatin-based combination chemotherapy remains the standard of care in first-line metastatic urothelial carcinoma (mUC) with response rates of approximately 50% and a median overall survival of 13–15 months . However, due to renal dysfunction, poor performance status and comorbidities, many patients will be considered cisplatin-ineligible and be offered regimens such as gemcitabine and carboplatin (GCa). Although better tolerated, GCa is inferior to cisplatin-based regimens, underscoring the need for novel therapeutic strategies in the cisplatin-ineligible setting .